Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study

Invest New Drugs. 1992 Apr;10(1):27-8. doi: 10.1007/BF01275475.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Drug Evaluation
  • Female
  • Humans
  • Hydroxyurea / administration & dosage
  • Hydroxyurea / adverse effects
  • Hydroxyurea / analogs & derivatives*
  • Lung Neoplasms / drug therapy*
  • Male
  • Middle Aged

Substances

  • Antineoplastic Agents
  • caracemide
  • Hydroxyurea